ArticleMolecular cancer research : MCR2019
NME1 Drives Expansion of Melanoma Cells with Enhanced Tumor Growth and Metastatic Properties.
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Histidine Phosphorylation: Protein Kinases and Phosphatases.International journal of molecular sciences · 2024Review
- Article
- Reconstruction of the cell pseudo-space from single-cell RNA sequencing data with scSpace.Nature communications · 2023Article
- RETRACTED: Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.PloS one · 2023Article
- Metabolic remodeling of pyrimidine synthesis pathway and serine synthesis pathway in human glioblastoma.Scientific reports · 2022Article
- Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.International journal of molecular sciences · 2022Article
- Heterogeneity in Melanoma.Cancers · 2022Review
- Epithelial-mesenchymal transition interaction with CD8+ T cell, dendritic cell and immune checkpoints in the development of melanoma.Cancer biomarkers : section A of Disease markers · 2022Article
- Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.Scientific reports · 2021Article
- Enrichment of Melanoma Stem-Like Cells via Sphere Assays.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Comprehensive analysis of theTranslational cancer research · 2020Article
- Article
- A rare subpopulation of melanoma cells with low expression of metastasis suppressor NME1 is highly metastatic in vivo.Scientific reports · 2020Article
- Long Noncoding RNA LINC00261 Reduces Proliferation and Migration of Breast Cancer Cells via the NME1-EMT Pathway.Cancer management and research · 2020Article
- Bioinformatic Analysis Identifies Potential Key Genes in the Pathogenesis of Melanoma.Frontiers in oncology · 2020Article
- Metabolic Compartmentalization at the Leading Edge of Metastatic Cancer Cells.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Melanoma is a lethal skin cancer prone to progression and metastasis, and resistant to therapy. Metastasis and therapy resistance of melanoma and other cancers are driven by tumor cell plasticity, largely via acquisition/loss of stem-like characteristics and transitions between epithelial and mesenchymal phenotypes (EMT/MET). NME1 is a metastasis suppressor gene that inhibits metastatic potential when its expression is enforced in melanoma and other cancers. Herein, we have unmasked a novel role for NME1 as a driver of melanoma growth distinct from its canonical function as a metastasis suppressor. NME1 promotes expansion of stem-like melanoma cells that exhibit elevated expression of stem cell markers (e.g., Sox2, Sox10, Oct-4, KLF4, and Ccnb-1), enhanced growth as melanoma spheres in culture, and enhanced tumor growth and lung colonizing activities
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.